Call Now

Human GPNMB / Osteoactivin Protein (His Tag)

HGFIN,NMB,Osteoactivin

Catalog Number P11305-H08H
Organism Species Human
Host Human Cells
Synonyms HGFIN,NMB,Osteoactivin
Molecular Weight The recombinant human GPNMB consists of 464 amino acids and predictes a molecular mass of 52.1 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhGPNMB is approximately 85-90 kDa due to glycosylation.
predicted N Ala 22
SDS-PAGE
Purity > 98 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the human GPNMB isoform 2 (Q14956-2) extracellular domain (Met 1-Pro 474) was fused with a polyhistidine tag at the C-terminus.
Bio-activity
Research Area Developmental Biology |Organogenesis |Skeletal development |Other Bone Remodeling Molecules
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background GPNMB belongs to the PMEL / NMB family, also known as Osteoactivin and Hematopoietic growth factor-inducible neurokinin 1 ( HGFIN ), is a transmembrane glycoprotein that is expressed in numerous cells, including osteoclasts, macrophages, dendritic cells, and tumor cells. It is suggested to influence osteoblast maturation, cell adhesion and migration. GPNMB protein acts as a downstream mediator of BMP-2 effects on osteoblast differentiation and function. GPNMB participates in bone mineralization, and functions as a negative regulator of inflammation in macrophages. Osteoactivin is expressed at high levels in normal and inflammatory liver macrophages suggesting a significant role in acute liver injury. The early-phase upregulation of Osteoactivin expression in the tubular epithelium in response to renal injury might play a role in triggering renal interstitial fibrosis via activation of matrix metalloproteinase expression and collagen remodeling in rats. Osteoactivin as a protein that is expressed in aggressive human breast cancers and is capable of promoting breast cancer metastasis to bone.
Reference
  • Pahl MV. et al., 2010, Clin J Am Soc Nephrol. 5(1): 56-61.
  • Abdelmagid SM. et al., 2008, Exp Cell Res. 314(13): 2334-51.
  • Haralanova-Ilieva B. et al., 2005, J Hepatol. 242(4): 565-72.
  • Abdelmagid SM. et al., 2007, J Cell Physiol. 210(1): 26-37.
  • Furochi H. et al., 2007, J Med Invest. 54(3-4): 248-54.